Furafylline

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Furafylline
DrugBank Accession Number
DB14029
Background

Furafylline is a derivative of methylxanthine derivative. It was developed on the context of asthma as a long-acting alternative for theophylline.

Type
Small Molecule
Groups
Experimental
Structure
Thumb
Weight
Average: 293.345
Monoisotopic: 293.13282569
Chemical Formula
C18H16FN3
Synonyms
  • Furafilina
  • Furafylline
  • Furafyllinum

Pharmacology

Indication

Not Available

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
1,2-BenzodiazepineThe therapeutic efficacy of Benzodiazepine can be decreased when used in combination with Furafylline.
AbirateroneThe serum concentration of Furafylline can be increased when it is combined with Abiraterone.
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Furafylline.
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Furafylline.
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Furafylline.
AcetazolamideAcetazolamide may increase the excretion rate of Furafylline which could result in a lower serum level and potentially a reduction in efficacy.
AcyclovirThe metabolism of Acyclovir can be decreased when combined with Furafylline.
AdalimumabThe serum concentration of Furafylline can be decreased when it is combined with Adalimumab.
AdenosineThe therapeutic efficacy of Adenosine can be decreased when used in combination with Furafylline.
AgomelatineThe serum concentration of Agomelatine can be increased when it is combined with Furafylline.
Interactions
Improve patient outcomes
Build effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
C2087G0XX3
CAS number
80288-49-9
InChI Key
HMZQULPVMKITSP-UHFFFAOYSA-N
InChI
InChI=1S/C18H16FN3/c19-18-16(12-3-1-11(9-20)2-4-12)7-13(10-21-18)15-8-14-5-6-17(15)22-14/h1-4,7,10,14-15,17,22H,5-6,8H2
IUPAC Name
4-(5-{7-azabicyclo[2.2.1]heptan-2-yl}-2-fluoropyridin-3-yl)benzonitrile
SMILES
FC1=C(C=C(C=N1)C1CC2CCC1N2)C1=CC=C(C=C1)C#N

References

General References
  1. Sesardic D, Boobis AR, Murray BP, Murray S, Segura J, de la Torre R, Davies DS: Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man. Br J Clin Pharmacol. 1990 Jun;29(6):651-63. [PubMed:2378786]
ChemSpider
23262468
BindingDB
50171007
ChEMBL
CHEMBL372638
Wikipedia
Furafylline

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00961 mg/mLALOGPS
logP2.69ALOGPS
logP3.06ChemAxon
logS-4.5ALOGPS
pKa (Strongest Basic)10.52ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area48.71 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity83.61 m3·mol-1ChemAxon
Polarizability31.36 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Racha JK, Rettie AE, Kunze KL: Mechanism-based inactivation of human cytochrome P450 1A2 by furafylline: detection of a 1:1 adduct to protein and evidence for the formation of a novel imidazomethide intermediate. Biochemistry. 1998 May 19;37(20):7407-19. doi: 10.1021/bi973011m. [PubMed:9585555]
  2. Fairman DA, Collins C, Chapple S: Progress curve analysis of CYP1A2 inhibition: a more informative approach to the assessment of mechanism-based inactivation? Drug Metab Dispos. 2007 Dec;35(12):2159-65. doi: 10.1124/dmd.107.017236. Epub 2007 Sep 6. [PubMed:17823234]
  3. Kunze KL, Trager WF: Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline. Chem Res Toxicol. 1993 Sep-Oct;6(5):649-56. [PubMed:8292742]
  4. Pilocarpine pharmacology review, FDA [File]

Drug created on May 15, 2018 22:28 / Updated on February 21, 2021 18:54